Financial Comparison: Ironwood Pharmaceuticals (NASDAQ:IRWD) & Mawson Infrastructure Group (OTCMKTS:WIZP)

Mawson Infrastructure Group (OTCMKTS:WIZP) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Mawson Infrastructure Group and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mawson Infrastructure Group	N/A	N/A	-85.32%
Ironwood Pharmaceuticals	-0.65%	-0.96%	0.74%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Mawson Infrastructure Group and Ironwood Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mawson Infrastructure Group	0	0	0	0	0.00
Ironwood Pharmaceuticals	0	6	2	0	2.25

Ironwood Pharmaceuticals has a consensus price target of $4.78, suggesting a potential upside of 537.78%. Given Ironwood Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Mawson Infrastructure Group.

Risk and Volatility

Mawson Infrastructure Group has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Earnings & Valuation

This table compares Mawson Infrastructure Group and Ironwood Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mawson Infrastructure Group	N/A	N/A	-$3.45 million	($0.33)	-1.23
Ironwood Pharmaceuticals	$351.41 million	0.35	-$1.00 billion	($0.03)	-25.00

Mawson Infrastructure Group has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Mawson Infrastructure Group, indicating that it is currently the more affordable of the two stocks.

Summary

Ironwood Pharmaceuticals beats Mawson Infrastructure Group on 6 of the 11 factors compared between the two stocks.

About Mawson Infrastructure Group

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.